Therefore, the promising outcomes of novel therapeutic approaches using PCSK9 inhibitors can improve the severity of the FH phenotype through lowering LDL-C, thus preventing the progression of CAD. The gene discussed is PCSK9; the disease is familial hyperaldosteronism.